Chronic Disease in Ireland: How to Achieve Better Outcomes



Patricia M Kearney patricia.kearney@ucc.ie March 14th, 2024

Professor of Epidemiology School of Public Health, UCC



How it started



High blood pressure 2nd leading risk factor for death and disability ≻Global Burden of Hypertension, Lancet 2005

Global burden of hypertension: analysis of worldwide data

Patricia M Keamey, Megan Whelton, Kristi Reynolds, Paul Muntner, Paul K Whelton, Jiang He

Summary

Background Reliable information about the prevalence of hypertension in different world regions is essential to the development of national and international health policies for prevention and control of this condition. We aimed to pool data from different regions of the world to estimate the overall prevalence and absolute burden of hypertension in 2000, and to estimate the global burden in 2025.

Lancet 2005; 365: 217–23 Departments of Epidemiology (PM Kauney MJD, M Whelen BS, K Roynolds PHD, P Muntter PhD, Prof J He MD), and Medicine (PM Munter, Prof J H Whelen (PM Unterne, Prof J H Whelen Hypertension and Renal Center

	Crude rate of	hypertension	Age-standardise	d rate of hy	pertension	
	Men rate (SE)	Women rate (SE)	Overall rate (SE)	Men	Women	Overall
Established market	economies					
USA11,12	23·5% (1·2)	23.3% (0.9)	23.4% (0.9)	21.0%	19.7%	20.3%
Canada ¹³	26.0% (0.4)	18.0% (0.4)	22.0% (0.3)	23.5%	15.6%	21.4%
Spain ¹⁴	46·2% (1·8)	44·3% (1·4)	45·1% (1·1)	41.7%	39.0%	40.0%
England ¹⁵	43·4% (0·7)	35.0% (0.6)	38.8% (0.5)	34.7%	25.7%	29.6%
Germany ¹⁶	60.2% (0.8)	50.3% (0.8)	55-3% (0-6)	55.4%	56.6%	
Greece ¹⁷	30.2% (2.8)	27.1% (2.3)	28·4% (1·7)	18.5%	15.9%	16.9%
Italy ¹⁸	44·8% (0·9)	30.6% (0.8)	37.7% (0.5)	42.0%	43.3%	
Sweden ¹⁹	44·8% (1·6)	32.0% (1.5)	38.4% (1.1)	39.6%	40.9%	
Australia ^{20,21}	31.9% (0.5)	20.7% (0.4)		30.8%	20.1%	
Japan ²²	50.1% (0.3)	43·3% (0·3)		42.7%	35.0%	38.3%
India						
North India rural	⁴ 3·4% (0·6)	6.8% (0.7)	5.2% (0.5)	3.5%	7.5%	5.5%
North India urba	1 ²⁵ 25·0% (1·4)	22.3% (1.4)		24.5%	23.2%	23.8%
North India rural	⁶ 20·8% (1·3)	20.8% (1.3)	20.8% (0.9)	21.5%	24.9%	23.1%
West India urban	²⁷ 30·0% (1·2)	33.0% (1.7)	30.9% (1.0)	31.8%	27.8%	30.7%
West India rural ²⁸	24·0% (1·0)	17.0% (1.1)	21.0% (0.7)	23-3%	19.8%	22.0%
Latin American and	the Caribbean					
Mexico ²⁹	37.5% (0.6)	28.1% (0.5)	32.0% (0.4)	38.6%	30.1%	33.5%
Paraguay ³⁰	28.8% (0.5)	40.9% (0.9)	32.5% (0.5)	32-4%	41.9%	35.4%
Venezuela ³¹	45·2% (0·8)	28·9% (0·7)	36-9% (0-6)	47.7%	32.2%	39.7%
Middle eastern cres	cent					
Egypt ³²	25·7% (1·4)	26.9% (1.2)	26·3% (0·9)	25.9%	29.3%	27.4%
Turkey ³³	26.0% (1.5)	34.1% (1.9)	29.6% (1.2)	21.8%	30.9%	25.7%
China ³⁴	28.6% (0.7)	25.8% (0.7)	27.2% (0.5)	28.8%	26.6%	27.7%
Other Asian and isla	ands					
Korea ³⁵			19.8% (0.3)	21.8%	19.4%	
Thailand ³⁶	21·3% (1·3)	19·8% (1·0)	20.5% (1.6)	22.1%	21.4%	21.7
Taiwan ³⁷	33.1% (0.7)	28.0% (0.6)	30.5% (0.5)	27.1%	20.8%	23.7%
Sub-Saharan Africa						
South Africa ³⁸	22.9% (0.6)	24.6% (0.5)	23.9% (0.7)	22.9%	23.4%	23.1%
Cameroon ³⁹	17·9% (1·4)	11·2% (1·0)	14·1% (1·7)	18.5%	12.6%	15.0%
Cameroon ⁴⁰	14·2% (1·3)	16-3% (1-4)	15.4% (0.9)			
Tanzania ⁴¹	31·3% (1·7)	31.0% (1.5)	31.1% (1.1)	30.2%	32.3%	31.3%
Zimbabwe ⁴²	41·0% (2·5)	28.0% (2.3)	34.1% (1.7)	25.3%	41.0%	33.1%
Table 2. Rate of by	nertension in	people aged 20 y	ears and older in	world regions		

How it's going

- The Irish Longitudinal Study on Ageing
- Mitchelstown Cohort Study
- Healthy Ireland
- Chronic Disease Management Programme







Integrated Knowledge Translati

- These estimates were obtained through the secondary data analysis of the 5th wave of the Healthy Ireland survey conducted in 2018-2019 as part of the EPICC (Evidence for Policies to Prevent Chronic Conditions) study, funded by the Health Research Board.
- More detailed information on the data source and prevalence estimates stratified by deprivation status medical reimbursement status (GMS Medical Card), age, are available here (link):
- ➤ The EPICC team was asked by the National Clinical Advisor & Group Lead for Chronic Disease to provide prevalence estimates for the specified eight chronic conditions. These estimates informed The Integrated Care Programme for the Prevention and Management of Chronic Disease in the development of a new Programme for the Prevention and Management of Chronic Disease.

🎔 ESPRIT_UCC 🎔 UCCPublicHealth 🛛 🔀 Katarzyna.Gajewska@ucc.ie 🛛 🔀 Danko.Stamenic@ucc.ie

Increasing Rates of Chronic Disease



source: Public Health Agency of Canada from the 2010 report * Against the Growing Burden of Disease' by The Public Health Agency of Canada © Global Ni



Why Chronic Disease Prevention?









Healthy Ireland Initiatives

HSE

Integrated Care Programme for the Prevention and Management of Chronic Disease

HSE

Framework for Self Management support of Chronic Conditions

Sláintecare

Implementation Strategy

COLLABORATIVE DOCTORAL PROGRAMME IN CHRONIC DISEASE PREVENTION

What causes the most death and disability in Ireland?

What causes the most deaths?



Institute for Health Metrics and Evaluation (IHME). Ireland profile. Seattle, WA: IHME, University of Washington, 2023. Available from http://www.healthdata.org/Ireland. (Accessed 24/02/2024)

Top 10 risks contributing to Disability-Adjusted Life Years (DALYs) per 100k in 2019 and rate change 2009– 2019, all ages combined

Prevalence of any Chronic Disease (any of the eight prioritised chronic conditions)



Prevalence of Individual Chronic Conditions and Multi-morbidity by Age Group

All - 1 - 10	10.44			70.74	
All adults over 18	18-44 years old	45-64 years old	65-69 years old	/0-/4 years old	75+ years old
6.9 (6.1, 7.8)	7.9 (6.5, 9.3)	6.0 (4.7, 7.2)	6.4 (4.0, 8.9)	5.6 (3.1, 8.1)	6.3 (4.2, 8.4)
1.8 (1.4, 2.2)	0.3 (0.04, 0.5)	2 4 (1.5, 3.4)	5.6 (2.8, 8.4)	3.0 (1.3, 4.8)	4.6 (3.0, 6.1)
3.7 (3.2, 4.2)	0.7 (0.4, 1.0)	4.2 (3.0, 5.4)	5.7 (3.6, 7.8)	8.9 (6.2, 11.6)	14.5 (11.9, 17.2)
0.6 (0.4, 0.8)	0.2 (0.01, 0.4)	0.7 (0.3, 1.0)	1.2 (0.1, 2.2)	1.0 (0.2, 1.8)	2.2 (1.2, 3.2)
4.6 (4.1, 5.2)	0.4 (0.2, 0.7)	6.4 (5.0, 7.7)	11.4 (8.4, 14.4)	13.2 (9.9, 16.6)	12.7 (10.3, 15.2)
0.4 (0.2, 0.5)	0.04 (0.01, 0.09)	0.2 (0.04, 0.5)	1.1 (0.2, 2.0)	0.4 (0.01, 1.2)	2.1 (0.9, 3.3)
0.8 (0.5, 1.0)	0.02 (0.01, 0.05)	0.7 (0.2, 1.2)	1.7 (0.7, 2.8)	2.2 (0.9, 3.5)	3.7 (2.3, 5.1)
1.8 (1.4, 2.2)	0.5 (0.2, 0.8)	1.7 (0.9, 2.5)	3.1 (1.4, 4.8)	5.0 (2.7, 7.4)	7.4 (5.1, 9.8)
13.9 (12.9, 14.9)	9.2 (7.8, 10.6)	14.4 (12.5, 16.2)	23.0 (18.8, 27.2)	22.7 (18.4, 26.9)	28.7 (25.0, 32.4)
2.1 (1.7, 2.5)	0.3 (0.06, 0.6)	2.6 (1.6, 3.7)	4.9 (3, 6.8)	5.1 (3.2, 7)	6.6 (4.9, 8.3)
0.7 (0.5, 0.9)	0.03 (0.01, 0.08)	0.8 (0.2, 1.3)	1.1 (0.01, 2.1)	2.0 (0.5, 3.6)	3.4 (2.1, 4.7)
	All adults over 18 6.9 (6.1, 7.8) 1.8 (1.4, 2.2) 3.7 (3.2, 4.2) 0.6 (0.4, 0.8) 4.6 (4.1, 5.2) 0.4 (0.2, 0.5) 0.8 (0.5, 1.0) 1.8 (1.4, 2.2) 13.9 (12.9, 14.9) 2.1 (1.7, 2.5) 0.7 (0.5, 0.9)	All adults over 1818-44 years old6.9 (6.1, 7.8)7.9 (6.5, 9.3)1.8 (1.4, 2.2)0.3 (0.04, 0.5)3.7 (3.2, 4.2)0.7 (0.4, 1.0)0.6 (0.4, 0.8)0.2 (0.01, 0.4)4.6 (4.1, 5.2)0.4 (0.2, 0.7)0.4 (0.2, 0.5)0.04 (0.01, 0.09)0.8 (0.5, 1.0)0.02 (0.01, 0.05)1.8 (1.4, 2.2)0.5 (0.2, 0.8)13.9 (12.9, 14.9)9.2 (7.8, 10.6)2.1 (1.7, 2.5)0.3 (0.06, 0.6)0.7 (0.5, 0.9)0.03 (0.01, 0.08)	All adults over 1818-44 years old45-64 years old6.9 (6.1, 7.8)7.9 (6.5, 9.3)6.0 (4.7, 7.2)1.8 (1.4, 2.2)0.3 (0.04, 0.5)2.4 (1.5, 3.4)3.7 (3.2, 4.2)0.7 (0.4, 1.0)4.2 (3.0, 5.4)0.6 (0.4, 0.8)0.2 (0.01, 0.4)0.7 (0.3, 1.0)4.6 (4.1, 5.2)0.4 (0.2, 0.7)6.4 (5.0, 7.7)0.4 (0.2, 0.5)0.04 (0.01, 0.09)0.2 (0.04, 0.5)0.8 (0.5, 1.0)0.02 (0.01, 0.05)0.7 (0.2, 1.2)1.8 (1.4, 2.2)0.5 (0.2, 0.8)1.7 (0.9, 2.5)13.9 (12.9, 14.9)9.2 (7.8, 10.6)14.4 (12.5, 16.2)2.1 (1.7, 2.5)0.3 (0.06, 0.6)2.6 (1.6, 3.7)0.7 (0.5, 0.9)0.03 (0.01, 0.08)0.8 (0.2, 1.3)	All adults over 1818-44 years old45-64 years old65-69 years old6.9 (6.1, 7.8)7.9 (6.5, 9.3)6.0 (4.7, 7.2)6.4 (4.0, 8.9)1.8 (1.4, 2.2)0.3 (0.04, 0.5)2.4 (1.5, 3.4)5.6 (2.8, 8.4)3.7 (3.2, 4.2)0.7 (0.4, 1.0)4.2 (3.0, 5.4)5.7 (3.6, 7.8)0.6 (0.4, 0.8)0.2 (0.01, 0.4)0.7 (0.3, 1.0)1.2 (0.1, 2.2)4.6 (4.1, 5.2)0.4 (0.2, 0.7)6.4 (5.0, 7.7)11.4 (8.4, 14.4)0.4 (0.2, 0.5)0.04 (0.01, 0.09)0.2 (0.04, 0.5)1.1 (0.2, 2.0)0.8 (0.5, 1.0)0.02 (0.01, 0.05)0.7 (0.2, 1.2)1.7 (0.7, 2.8)1.8 (1.4, 2.2)0.5 (0.2, 0.8)1.7 (0.9, 2.5)3.1 (1.4, 4.8)13.9 (12.9, 14.9)9.2 (7.8, 10.6)14.4 (12.5, 16.2)23.0 (18.8, 27.2)2.1 (1.7, 2.5)0.3 (0.06, 0.6)2.6 (1.6, 3.7)4.9 (3, 6.8)0.7 (0.5, 0.9)0.03 (0.01, 0.08)0.8 (0.2, 1.3)1.1 (0.01, 2.1)	All adults over 1818-44 years old45-64 years old65-69 years old70-74 years old6.9 (6.1, 7.8)7.9 (6.5, 9.3)6.0 (4.7, 7.2)6.4 (4.0, 8.9)5.6 (3.1, 8.1)1.8 (1.4, 2.2)0.3 (0.04, 0.5)2.4 (1.5, 3.4)5.6 (2.8, 8.4)3.0 (1.3, 4.8)3.7 (3.2, 4.2)0.7 (0.4, 1.0)4.2 (3.0, 5.4)5.7 (3.6, 7.8)8.9 (6.2, 11.6)0.6 (0.4, 0.8)0.2 (0.01, 0.4)0.7 (0.3, 1.0)1.2 (0.1, 2.2)1.0 (0.2, 1.8)4.6 (4.1, 5.2)0.4 (0.2, 0.7)6.4 (5.0, 7.7)11.4 (8.4, 14.4)13.2 (9.9, 16.6)0.4 (0.2, 0.5)0.04 (0.01, 0.09)0.2 (0.04, 0.5)1.1 (0.2, 2.0)0.4 (0.01, 1.2)0.8 (0.5, 1.0)0.02 (0.01, 0.05)0.7 (0.2, 1.2)1.7 (0.7, 2.8)2.2 (0.9, 3.5)1.8 (1.4, 2.2)0.5 (0.2, 0.8)1.7 (0.9, 2.5)3.1 (1.4, 4.8)5.0 (2.7, 7.4)H13.9 (12.9, 14.9)9.2 (7.8, 10.6)14.4 (12.5, 16.2)23.0 (18.8, 27.2)22.7 (18.4, 26.9)2.1 (1.7, 2.5)0.3 (0.06, 0.6)2.6 (1.6, 3.7)4.9 (3, 6.8)5.1 (3.2, 7)0.7 (0.5, 0.9)0.03 (0.01, 0.08)0.8 (0.2, 1.3)1.1 (0.01, 2.1)2.0 (0.5, 3.6)

*COPD = chronic obstructive pulmonary disease

**CHD = coronary heart disease (heart attack or chronic consequences of heart attack or other heart trouble)

***TIA = transient ischemic attack

Prevalence of Chronic Disease by Age Group



Prevalence of Chronic Disease by Gender

Condition	Female	Male
Asthma	7.9 (6.7, 9)	6.0 (4.8, 7.1)
COPD*	1.5 (1.0, 2.1)	2.0 (1.4, 2.6)
CHD**	2.4 (1.9, 2.9)	5.0 (4.1, 5.8)
Stroke	0.6 (0.4, 0.9)	0.6 (0.3, 0.9)
Diabetes	3.4 (2.8, 4.1)	5.9 (4.9, 6.8)
Heart failure	0.3 (0.2, 0.5)	0.4 (0.2, 0.6)
TIA***	0.5 (0.3, 0.8)	1.0 (0.6, 1.3)
Atrial Fibrillation	1.5 (1.0, 2.0)	2.1 (1.5, 2.8)
Multimorbidity		
At least 1 condition	13.2 (11.8, 14.6)	14.7 (13.1, 16.2)
At least 2 conditions	1.7 (1.2, 2.2)	2.5 (1.8, 3.1)
At least 3 conditions	0.4 (0.2, 0.6)	1.0 (0.6, 1.4)

Prevalence of Chronic Disease by Deprivation Level (HP Pobal Deprivation Index)

Chronic	Extremely	Very	Affluent ^c	Marginally	Marginally	Disadvantaged ^f	Very	Extremely
Condition	affluent ^a	affluent ^b		above average ^d	below average ^e		disadvantaged ^g	disadvantaged ^h
Asthma	8.3	7.0	4.5	6.9	6.0	6.3	7.3	11.0
	(4.2, 12.4)	(4.4, 9.6)	(2.6, 6.3)	(5.2, 8.6)	(4.5, 7.5)	(4.1, 8.4)	(4.9, 9.8)	(7.2, 14.8)
COPD	1.0	0.01	1.0	1.6	1.7	1.1	2.4	3.9
	(0.01, 2.4)	(0.04, 2.4)	(0.3, 1.7)	(0.7, 2.5)	(0.8, 2.6)	(0.5, 1.7)	(1.1, 3.7)	(2.1, 5.7)
CHD	2.1	2.7	2.3	3.1	3.9	4.4	5.2	5.1
	(0.9, 3.4)	(1.3, 4.2)	(1.2, 3.3)	(2.3, 3.9)	(2.7, 5.0)	(3.0, 5.9)	(3.2, 7.3)	(2.8, 7.4)
Stroke	0	0.01	0.6	0.5	0.8	0.6	1.0	0.8
	(0, 0)	(0.2, 1.0)	(0.01, 1.2)	(0.2, 0.9)	(0.4, 1.2)	(0.04, 1.1)	(0.3, 1.7)	(0.01, 1.6)
Diabetes	2.0	4.0	4.4	4.5	4.9	4.1	5.8	6.0
	(0.8, 3.1)	(1.9, 6.1)	(2.7, 6.2)	(3.2, 5.7)	(3.7, 6.2)	(2.8, 5.5)	(4.1, 7.5)	(3.7, 8.4)
Heart failure	0.1	0.01	0.4	0.2	0.3	0.2	0.7	0.7
	(0.01, 0.4)	(0.2, 1.0)	(0.01, 0.9)	(0.03, 0.4)	(0.01, 0.6)	(0.01, 0.4)	(0.1, 1.3)	(0.05, 1.3)
TIA	0.1	0.01	0.8	0.4	0.9	0.5	0.8	1.6
	(0.01, 0.3)	(0.3, 2.2)	(0.02, 1.5)	(0.2, 0.7)	(0.5, 1.2)	(0.07, 1.0)	(0.3, 1.4)	(0.3, 2.9)
Atrial	1.6	2.5	1.1	1.9	2.5	2.0	1.0	1.2
Fibrillation	(0.2, 2.9)	(0.8, 4.2)	(0.4, 1.7)	(1.1, 2.6)	(1.3, 3.7)	(0.9, 3.0)	(0.2, 1.7)	(0.3, 2.1)
Multimorbidity								
At least 1	12.1	4.4	11.2	3.8	1.8	13.6	16.8	19.6
condition	(7.6, 16.5)	(0.7, 18.2)	(8.5, 13.8)	(1.7, 15.9)	(9.9, 3.7)	(10.9, 16.3)	(3.4, 20.3)	(15.2, 24.1)
At least 2	0.8	1.8	1.2	1.8	3.2	1.6	2.0	3.2
conditions	(0.01, 1.8)	(0.4, 3.1)	(0.5, 1.8)	(0.9, 2.7)	(2.1, 4.3)	(0.8, 2.4)	(1.0, 2.9)	(1.4, 5.0)
At least 3	0.5	0.01	0.5	0.6	0.9	0.8	0.6	1.1
conditions	(0.01, 1.2)	(0.2, 1.0)	(0.01, 1.2)	(0.2, 0.9)	(0.3, 1.5)	(0.2, 1.5)	(0.09, 1.0)	(0.2, 2.1)

The Pobal HP Deprivation Index





Prevalence of Chronic Disease and Multi-morbidity by GMS Status

	Overall population		GMS†		Non-GMS	
Aged 18-44	Proportion %	Population++	Proportion %	Population	Proportion %	Population
	(95% CI)	n=1,798,793	(95% CI)	n=480,670	(95% CI)	n=1,318,123
Any of the 8 conditions or their combination	9.6 (8.1, 11.0)	172,375	11.6 (8.9, 14.4)	55,980	8.8 (7.1, 10.5)	116,395
Asthma	7.9 (6.5, 9.3)	142,015	8.5 (6.0, 10.9)	40,797	7.7 (6.1, 9.3)	101,218
COPD*	0.3 (0.04, 0.5)	4,805	0.3 (0.01, 0.7)	1,305	0.3 (0.01, 0.5)	3,499
CHD**	0.7 (0.4, 1.0)	12,321	1.0 (0.2, 1.8)	4,815	0.6 (0.2, 0.9)	7,505
Stroke	0.2 (0.01, 0.4)	3,665	0.6 (0.01, 1.4)	2,938	0.06 (0.01, 0.1)	727
Diabetes	0.4 (0.2, 0.7)	7,546	1.0 (0.3, 1.7)	4,821	0.2 (0.03, 0.4)	2,725
Heart failure	0.04 (0.01, 0.09)	642	0.1 (0.01, 0.3)	642	0	0
TIA***	0.02 (0.01, 0.05)	295	0	0	0.02 (0.01, 0.07)	295
Atrial Fibrillation	0.5 (0.2, 0.8)	8,213	0.8 (0.02, 1.5)	3,743	0.3 (0.03, 0.6)	4,470
Any unique condition	9.2 (7.8, 10.6)	165,849	11.1 (8.4, 13.8)	53,203	8.5 (6.9, 10.2)	112,646
Asthma only	7.6 (6.3, 9.0)	137,294	8.1 (5.7, 10.5)	39,035	7.5 (5.8, 9.1)	98,259
COPD only	0.3 (0.04, 0.5)	4,805	0.3 (0.01, 0.7)	1,305	0.3 (0.01, 0.5)	3,499
CHD only	0.6 (0.3, 0.9)	10,811	0.8 (0.06, 1.5)	3,801	0.5 (0.2, 0.9)	7,010
Stroke only	0.1 (0.01, 0.2)	1,875	0.3 (0.01, 0.7)	1,443	0.03 (0.01, 0.1)	432
Diabetes only	0.3 (0.1, 0.5)	5,483	0.8 (0.1, 1.5)	3,845	0.1 (0.01, 0.3)	1,638
Heart failure only	0.02 (0.01, 0.06)	336	0.07 (0.01, 0.2)	336	0	0
TIA only	0	0	0	0	0	0
Atrial Fibrillation only	0.3 (0.05, 0.5)	5,245	0.7 (0.01, 1.5)	3,438	0.1 (0.01, 0.3)	1,807
Multi-morbidity						
Two or more of the 8 conditions	0.4 (0.09, 0.6)	6,526	0.6 (0.01, 1.3)	2,777	0.3 (0.01, 0.6)	3,749
Three or more of the 8 conditions	0.03 (0.01, 0.08)	601	0.06 (0.01, 0.2)	306	0.02 (0.01, 0.07)	295
Four or more of the 8 conditions	0	0	0	0	0 (0, 0)	0

Prevalence of Chronic Disease and Multi-morbidity by GMS Status

	Overall population		GMS†		Non-GMS	
Aged 45-64	Proportion %	Population ⁺⁺	Proportion %	Population	Proportion %	Population
	(95% CI)	n=1,135,003	(95% CI)	n=358,839	(95% CI)	n=776,164
Any of the 8 conditions or their combination	17.8 (15.8, 19.9)	202,303	30.0 (25.6, 34.5)	107,828	12.2 (10.1, 14.3)	94,475
Asthma	6.0 (4.7, 7.2)	67,651	9.6 (6.7, 12.5)	34,406	4.3 (3.0, 5.5)	33,246
COPD*	2.4 (1.5, 3.4)	27,661	5.6 (3.0, 8.1)	19,916	1.0 (0.3, 1.7)	7,745
CHD**	4.2 (3.0, 5.4)	47,846	9.0 (5.9, 12.1)	32,196	2.0 (1.1, 2.9)	15,651
Stroke	0.7 (0.3, 1.0)	7,734	1.6 (0.6, 2.5)	5,592	0.3 (0.02, 0.5)	2,142
Diabetes	6.4 (5.0, 7.7)	72,189	11.3 (8.2, 14.3)	40,450	4.1 (2.7, 5.4)	31,739
Heart failure	0.2 (0.04, 0.5)	2,829	0.3 (0.01, 0.7)	1,228	0.2 (0.01, 0.5)	1,601
TIA***	0.7 (0.2, 1.2)	8,220	1.2 (0.4, 2.1)	4,458	0.5 (0.01, 1.1)	3,762
Atrial Fibrillation	1.7 (0.9, 2.5)	19,013	2.5 (0.7, 4.4)	9,145	1.3 (0.5, 2.1)	9,868
Any unique condition	14.4 (12.5, 16.2)	162,883	21.7 (17.8, 25.5)	77,736	11.0 (9.0, 12.9)	85,148
Asthma only	4.5 (3.5, 5.5)	51,222	5.9 (3.8, 8.0)	21,160	3.9 (2.7, 5.0)	30,062
COPD only	1.2 (0.6, 1.8)	13,110	2.0 (0.7, 3.4)	7,327	0.7 (0.1, 1.4)	5,783
CHD only	2.6 (1.7, 3.5)	29,735	5.3 (2.9, 7.7)	19,038	1.4 (0.7, 2.0)	10,697
Stroke only	0.2 (0.05, 0.4)	2,628	0.3 (0.01, 0.6)	920	0.2 (0.01, 0.4)	1,709
Diabetes only	4.8 (3.7, 6.0)	54,810	7.2 (4.7, 9.7)	25,950	3.7 (2.5, 5.0)	28,860
Heart failure only	0.2 (0.01, 0.4)	2,036	0.1 (0.01, 0.4)	434	0.2 (0.01, 0.5)	1,601
TIA only	0.3 (0.01, 0.6)	3,135	0.4 (0.01, 0.8)	1,315	0.2 (0.01, 0.7)	1,821
Atrial Fibrillation only	0.5 (0.2, 0.9)	6,207	0.4 (0.01, 0.9)	1,592	0.6 (0.2, 1.0)	4,615
Multi-morbidity						
Two or more of the 8 conditions	3.5 (2.3, 4.6)	39,419	8.4 (5.3, 11.5)	30,092	1.2 (0.4, 2.0)	9,327
Three or more of the 8 conditions	0.8 (0.3, 1.4)	9,461	2.1 (0.7, 3.4)	7,510	0.3 (0.01, 0.7)	1,952
Four or more of the 8 conditions	0.07 (0.01, 0.2)	793	0.2 (0.01, 0.5)	793	0	0

*COPD = chronic obstructive pulmonary disease

**CHD = coronary heart disease (heart attack or chronic consequences of heart attack or other heart trouble)

*******TIA = transient ischemic attack

†GMS = having a medical card or a GP-visit card

⁺⁺ Data from Census 2016, CSO

Prevalence of Chronic Disease and Multimorbidity by GMS status



Integrated Knowledge Translation





Use of healthcare services over the past year by CVD diagnosis

Healthcare service	No CVD	CVD	Overall				
	N = 6,655	N = 1,458	N = 8,113				
<u>GP visits</u>							
Mean (SD) number	3.4 (3.8)	5.7 (5.0)	3.9 (4.1)				
Attended	5,703 (86%)	1,391 (95%)	7,094 (87%)				
A&E Department attendance							
Mean (SD) number	0.2 (0.6)	0.4 (0.9)	0.2 (0.7)				
Attended	871 (13%)	348 (24%)	1,219 (15%)				
OPD visits:							
Mean (SD) number	1.0 (2.0)	2.1 (2.8)	1.2 (2.2)				
Attended	2,446 (37%)	880 (60%)	3,326 (41%)				
Hospital overnight admissions:							
Mean (SD) number	0.2 (0.6)	0.4 (0.9)	0.2 (0.6)				
Admitted	686 (10%)	362 (25%)	1,048 (13%)				
Results presented as n (%) unless indicated otherwise;							

CVD, cardiovascular disease; GP, general practitioner; A&E, accident and emergency; OPD , outpatient department

Incremental healthcare service use and costs attributable to CVD

Health service	Average ma	rginal effect (95% CI)	Direct costs, 2023 (95% Cl)			
	Univariate	Multivariable	Costs per person (€)	Costs overall (million €)	% total	
GP visits	1.98 (1.76, 2.2)	1.19 (0.99, 1.39)	€71.6 (€59.7, €83.6)	€22.2 (€18.5, €25.9)	6.3%	
OPD visits	0.85 (0.72, 0.98)	0.79 (0.65, 0.93)	€150.8 (€124.1, €177.6)	€46.8 (€38.5, €55.1)	13.3%	
A&E attendances	0.17 (0.13, 0.2)	0.14 (0.10, 0.18)	€31.2 (€23, €39.4)	€9.7 (€7.1, €12.2)	2.7%	
Hospital admissions	0.18 (0.14, 0.21)	0.15 (0.11, 0.18)	€881.5 (€672.3, €1090.7)	€273.5 (€208.6, €338.5)	77.7%	
	Total		€1135.2 (€879, 1391.3)	€352.2 (€272.8, €431.7)	100.0%	

CI, confidence interval; GP, general practitioner; A&E, accident and emergency department; OPD, outpatient department.

Multivariable model adjusted for participant gender and age, household location, education level, marital status, healthcare cover, other chronic conditions and the interaction terms of age and gender with CVD.

Cost estimates based on average marginal effects from multivariable models.

Incremental Use of Healthcare Services attributable to CVD and associated costs by Gender



Incremental use of healthcare services attributable to CVD and associated costs by age group



Acknowledgements

This work was supported by a research grant from the Irish Health Research Board (reference: SDAP-2019-030).

EPICC Team: Post-doctoral Researchers Danko Stamenic, Katarzyna A. Gajewska



UCC Co-PIs Anthony P. Fitzgerald, Kate N. O'Neill, Sheena M. McHugh, Linda M. O'Keeffe, Jodi Cronin, Margaret Bermingham, Brenda M. Lynch,

HSE Collaborators/Knowledge Users Orlaith O'Reilly, Sarah M. O'Brien, Claire M. Buckley, Paul M. Kavanagh



PhD Trainees



Irene Gibson

Cardiovascular nurse specialist Developing and implementing a digital intervention for secondary prevention of CVD

University of Galway



Eanna Kenny

- Health psychologist
- Optimising digital cardiac rehabilitation using the Multiphase Optimisation Strategy
- University of Galway



Pauline Dunne

- Dietician
- Evaluating the feasibility of a type 2 diabetes prevention pathway, after pregnancy with GDM
 UCD



Edel Burton

- Pharmacist
- Impact of COVID-19 on prehospital emergency care for stroke/TIA
- UCC



Clair Haseldine

- Physiotherapist
- Implementation of digital diabetes prevention programmes to improve engagement
- UCC



Marcia Carvalho

- Health psychologist
- SUSTAIN T2DM using behaviour science to understand maintenance of self-management behaviours
- University of Galway



The Collaborative Doctoral Programme in Chronic Disease Prevention (CDP-CDP) is supported by funding from the Health Research Board (HRB) and is delivered in collaboration with the HRB Structured Population and Health-services Research Education Programme (SPHeRE Programme).











